{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hRPC&page=27", "query": { "intervention": "hRPC", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 862, "total_pages": 87, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hRPC&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hRPC&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T17:06:53.755Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01505868", "title": "Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Lymphadenopathy", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Prostate Carcinoma Metastatic in the Bone", "Prostate Small Cell Carcinoma" ], "interventions": [ { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 170, "start_date": "2012-07-11", "completion_date": "2019-12-09", "has_results": true, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 2, "location_summary": "Detroit, Michigan • Houston, Texas", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01505868" }, { "nct_id": "NCT04104776", "title": "A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Diffuse Large B Cell Lymphoma", "Lymphoma, T-Cell", "Mesothelioma, Malignant", "Prostatic Neoplasms, Castration-Resistant", "Endometrial Cancer", "Ovarian Clear Cell Carcinoma", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Tulmimetostat", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2019-09-18", "completion_date": "2030-02-27", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 22, "location_summary": "Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04104776" }, { "nct_id": "NCT02788409", "title": "Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Not applicable for study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "MALE", "summary": "65 Years and older · Male only" }, "enrollment_count": 2234, "start_date": "2016-05-15", "completion_date": "2018-05-09", "has_results": false, "last_update_posted_date": "2019-05-08", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788409" }, { "nct_id": "NCT05919264", "title": "FOG-001 in Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Colorectal Cancer", "Solid Tumor", "Locally Advanced Solid Tumor", "Metastatic Cancer", "WNT Pathway", "HCC", "Desmoid", "Microsatellite Stable Colorectal Cancer", "Metastatic Castration-resistant Prostate Cancer", "Familial Adenomatous Polyposis (FAP)", "Endometrial Carcinoma", "Prostate Cancer", "Microsatellite Instability-High Colorectal Cancer", "Adamantinomatous Craniopharyngioma" ], "interventions": [ { "name": "FOG-001", "type": "DRUG" }, { "name": "mFOLFOX-6", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Trifluridine/tipiracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Parabilis Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 619, "start_date": "2023-05-23", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05919264" }, { "nct_id": "NCT02106507", "title": "ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "apalutamide", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 9, "start_date": "2014-04", "completion_date": "2021-06-28", "has_results": false, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02106507" }, { "nct_id": "NCT05848011", "title": "A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Androgen-Independent Prostatic Cancer", "Androgen-Independent Prostatic Neoplasms", "Prostate Cancer Recurrent", "Androgen-Insensitive Prostatic Cance", "Androgen-Resistant Prostatic Cancer", "Hormone Refractory Prostatic Cancer", "Immunotherapy", "Immune Checkpoint Inhibitor", "Inhibitory Checkpoint Molecule" ], "interventions": [ { "name": "lorigerlimab", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 154, "start_date": "2023-09-28", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 10, "location_summary": "Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Island", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05848011" }, { "nct_id": "NCT04634344", "title": "Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "DZD2269", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dizal Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2021-04-12", "completion_date": "2022-05-05", "has_results": false, "last_update_posted_date": "2022-07-11", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 2, "location_summary": "New York, New York • Pittsburgh, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634344" }, { "nct_id": "NCT06029998", "title": "Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 22, "start_date": "2024-03-11", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06029998" }, { "nct_id": "NCT02607228", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castrate-Resistant Prostate Cancer" ], "interventions": [ { "name": "Alobresib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 31, "start_date": "2015-12-08", "completion_date": "2019-09-03", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 4, "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607228" }, { "nct_id": "NCT02913196", "title": "Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2016-12-30", "completion_date": "2025-10-15", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-26T17:06:53.755Z", "location_count": 2, "location_summary": "Omaha, Nebraska • New York, New York", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02913196" } ] }